Back to today’s briefing

Story perspectives

Pfizer Beats Revenue Estimates, Targets $30 Amid Deal

10/7/2025

50 11 Full Breakdown

Summary

Story summary

Pfizer Inc. (NYSE:PFE) has a consensus Hold from 19 analysts, with a $28.41 target.
Bank of America raised its target to $30.00 from $28.00, implying about 9.63% upside.
Quarterly revenue reached $14.65B, beating $13.43B estimates, with a 16.84% net margin and EPS of $0.78. Institutional owners hold 68.36%; Pfizer also secured a White House tariff-avoidance deal and set FY2025 EPS guidance 2.90-3.10.

History

Historical Context

Founded in 1849, Pfizer Inc. has evolved from a fine chemicals manufacturer to a leading pharmaceutical company, significantly impacting global health. In 2021, Pfizer reported $81.29 billion in revenue, largely due to its COVID-19 vaccine, Comirnaty. The U.S. government purchased 600 million doses, highlighting Pfizer's crucial role in addressing public health crises and shaping the pharmaceutical industry's future.

1 of 2

Story summary

Pfizer Inc. (NYSE:PFE) has a consensus Hold from 19 analysts, with a $28.41 target.
Bank of America raised its target to $30.00 from $28.00, implying about 9.63% upside.
Quarterly revenue reached $14.65B, beating $13.43B estimates, with a 16.84% net margin and EPS of $0.78. Institutional owners hold 68.36%; Pfizer also secured a White House tariff-avoidance deal and set FY2025 EPS guidance 2.90-3.10.

1 / 2